|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0013216,
umls-concept:C0029456,
umls-concept:C0085552,
umls-concept:C0102118,
umls-concept:C0246719,
umls-concept:C0439849,
umls-concept:C0439851,
umls-concept:C0445223,
umls-concept:C0521170,
umls-concept:C0566588,
umls-concept:C1273870,
umls-concept:C1321605,
umls-concept:C1552596,
umls-concept:C1552599,
umls-concept:C1704787,
umls-concept:C1706077,
umls-concept:C1707455,
umls-concept:C1947931,
umls-concept:C2603343
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-8-18
|
|
pubmed:abstractText |
This population-based study aimed to compare direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate. During a 2-year follow-up period, compared to those with medication possession ratio (MPR) > or = 80%, women with MPR < 80% incurred significantly higher physician care costs and hospital care costs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1433-2965
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1571-81
|
|
pubmed:meshHeading |
pubmed-meshheading:19107385-Aged,
pubmed-meshheading:19107385-Alendronate,
pubmed-meshheading:19107385-Bone Density Conservation Agents,
pubmed-meshheading:19107385-Confidence Intervals,
pubmed-meshheading:19107385-Etidronic Acid,
pubmed-meshheading:19107385-Female,
pubmed-meshheading:19107385-Fractures, Bone,
pubmed-meshheading:19107385-Health Care Costs,
pubmed-meshheading:19107385-Humans,
pubmed-meshheading:19107385-Male,
pubmed-meshheading:19107385-Osteoporosis,
pubmed-meshheading:19107385-Risk Factors
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
|
|
pubmed:affiliation |
Faculty of Pharmacy, University of Montreal, PO Box 6128, Centre-Ville Station, Montreal, Quebec, Canada, H3C 3J7.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
